Payment overview · 2025
General Payments
$88.09
4 reported records · 4 companies
Healthcare provider profile · identity verified
Imaduddin Syed Hashmi, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1013198886
Verified facts
What the public records show
CMS Open Payments records show Imaduddin Syed Hashmi, MD received $88.09 in general payments during 2025 across 4 reported records.
Braeburn Inc. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Braeburn Inc. | Unresolved — no canonical attribution shown | $25.57 | 29.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $25.54 | 29.0% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $20.76 | 23.6% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $16.22 | 18.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.09 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 442 | 113 |
| Losartan Potassium | Losartan Potassium | 390 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 86 |
| Metformin Hcl | Metformin Hcl | 248 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 229 | 21 |
| Gabapentin | Gabapentin | 191 | 58 |
| Famotidine | Famotidine | 174 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 39 |
| Montelukast Sodium | Montelukast Sodium | 127 | 48 |
| Mounjaro | Tirzepatide | 119 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 114 | 41 |
| Vascepa | Icosapent Ethyl | 109 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 37 |
| Diclofenac Sodium Er | Diclofenac Sodium | 102 | 17 |
| Omeprazole | Omeprazole | 83 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 80 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 79 | 26 |
| Jardiance | Empagliflozin | 77 | 17 |
| Trulicity | Dulaglutide | 77 | 14 |
| Furosemide | Furosemide | 76 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 74 | suppressed |
| Ezetimibe | Ezetimibe | 73 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 33 |
| Januvia | Sitagliptin Phosphate | 66 | 15 |
| Chlorthalidone | Chlorthalidone | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Labetalol Hcl | Labetalol Hcl | 60 | 13 |
| Prednisone | Prednisone | 58 | 31 |
| Novolog Flexpen | Insulin Aspart | 56 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 56 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 14 |
| Ozempic | Semaglutide | 51 | 13 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 14 |
| Carvedilol | Carvedilol | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 25 |
| Meclizine Hcl | Meclizine Hcl | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 42 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 11 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Meloxicam | Meloxicam | 30 | 15 |
| Eliquis | Apixaban | 29 | suppressed |
| Lisinopril | Lisinopril | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 27 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Finasteride | Finasteride | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 22 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 22 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Ofloxacin | Ofloxacin | 15 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.09 · 4 records | Braeburn Inc. | APTIMA, BRIXADI, Flexitouch Plus, Nimbl, Zubsolv | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error